Clovis Oncology, Inc. (CLVS): Price and Financial Metrics


Clovis Oncology, Inc. (CLVS): $0.08

0.00 (-5.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLVS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLVS POWR Grades

  • Growth is the dimension where CLVS ranks best; there it ranks ahead of 74.53% of US stocks.
  • CLVS's strongest trending metric is Growth; it's been moving down over the last 138 days.
  • CLVS's current lowest rank is in the Sentiment metric (where it is better than 3.31% of US stocks).

CLVS Stock Summary

  • CLVS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.24 -- higher than only 3.15% of US-listed equities with positive expected earnings growth.
  • CLVS's price/sales ratio is 0.09; that's higher than the P/S ratio of merely 2.02% of US stocks.
  • CLOVIS ONCOLOGY INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -565.06%, greater than the shareholder yield of just 1.2% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to CLOVIS ONCOLOGY INC, a group of peers worth examining would be ALBO, SPRO, OVID, HCWB, and SRDX.
  • CLVS's SEC filings can be seen here. And to visit CLOVIS ONCOLOGY INC's official web site, go to www.clovisoncology.com.

CLVS Valuation Summary

  • In comparison to the median Healthcare stock, CLVS's EV/EBIT ratio is 143.48% lower, now standing at -3.
  • CLVS's price/sales ratio has moved NA NA over the prior 135 months.

Below are key valuation metrics over time for CLVS.

Stock Date P/S P/B P/E EV/EBIT
CLVS 2022-12-09 0.2 -0.1 -0.1 -3.0
CLVS 2022-12-08 0.2 -0.1 -0.1 -3.0
CLVS 2022-12-07 0.2 -0.1 -0.1 -3.0
CLVS 2022-12-06 0.3 -0.1 -0.1 -3.1
CLVS 2022-12-05 0.3 -0.1 -0.2 -3.1
CLVS 2022-12-02 0.4 -0.1 -0.2 -3.1

CLVS Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 31.41%.
  • Its 5 year price growth rate is now at -86.02%.
  • The 4 year price growth rate now stands at -86.02%.
Over the past 33 months, CLVS's revenue has gone down $9,985,000.

The table below shows CLVS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 133.021 -175.575 -251.906
2022-06-30 140.274 -181.034 -263.302
2022-03-31 144.951 -192.662 -258.418
2021-12-31 148.757 -196.057 -264.524
2021-09-30 156.088 -210.767 -299.093
2021-06-30 156.944 -219.022 -310.359

CLVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLVS has a Quality Grade of C, ranking ahead of 53.47% of graded US stocks.
  • CLVS's asset turnover comes in at 0.279 -- ranking 164th of 682 Pharmaceutical Products stocks.
  • NEOG, FLXN, and NSTG are the stocks whose asset turnover ratios are most correlated with CLVS.

The table below shows CLVS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.279 0.744 -0.373
2021-06-30 0.271 0.746 -0.388
2021-03-31 0.269 0.746 -0.423
2020-12-31 0.271 0.749 -0.454
2020-09-30 0.258 0.753 -0.415
2020-06-30 0.244 0.754 -0.408

CLVS Price Target

For more insight on analysts targets of CLVS, see our CLVS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 2.17 (Hold)

CLVS Stock Price Chart Interactive Chart >

Price chart for CLVS

CLVS Price/Volume Stats

Current price $0.08 52-week high $3.32
Prev. close $0.09 52-week low $0.08
Day low $0.08 Volume 24,516,400
Day high $0.10 Avg. volume 8,875,886
50-day MA $0.59 Dividend yield N/A
200-day MA $1.29 Market Cap 11.77M

Clovis Oncology, Inc. (CLVS) Company Bio


Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The company was founded in 2009 and is based in Boulder, Colorado.


CLVS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLVS Latest Social Stream


Loading social stream, please wait...

View Full CLVS Social Stream

Latest CLVS News From Around the Web

Below are the latest news stories about CLOVIS ONCOLOGY INC that investors may wish to consider to help them evaluate CLVS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

William White on InvestorPlace | December 14, 2022

CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy

Clovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection.

William White on InvestorPlace | December 12, 2022

Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.

Yahoo | December 12, 2022

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Yahoo | December 12, 2022

Clovis Plans to Sell Cancer Drug to Novartis in Bankruptcy Deal

(Bloomberg) -- Clovis Oncology Inc. filed for bankruptcy and plans to sell its experimental cancer drug at an auction with Novartis Innovative Therapies making a binding, opening bid worth as much as $681 million.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyElon Musk Is Ruining Trump’s Presidential CampaignUS Stocks Start Fed Week Higher as CPI Data Loom: Markets WrapFed’s Message That Rates Will S

Yahoo | December 12, 2022

Read More 'CLVS' Stories Here

CLVS Price Returns

1-mo N/A
3-mo -72.41%
6-mo -94.59%
1-year -96.10%
3-year -99.16%
5-year -99.84%
YTD N/A
2022 0.00%
2021 -43.54%
2020 -53.96%
2019 -41.95%
2018 -73.59%

Continue Researching CLVS

Here are a few links from around the web to help you further your research on Clovis Oncology Inc's stock as an investment opportunity:

Clovis Oncology Inc (CLVS) Stock Price | Nasdaq
Clovis Oncology Inc (CLVS) Stock Quote, History and News - Yahoo Finance
Clovis Oncology Inc (CLVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8278 seconds.